Indian drug companies are gearing up to transform diabetes treatment in India with cost-effective generic versions of Empagliflozin, as the patent for the key diabetes drug has expired. This move is expected to drastically reduce expenses and enhance accessibility for more than 10 crore diabetic patients across the country. Mankind Pharma and other pharmaceutical companies are all set to introduce the drug at a much lower price compared to the original, alleviating financial strains and promoting better heart and kidney health among patients. This development is poised to make a significant impact on the healthcare landscape in India, offering hope to millions battling diabetes.